U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unexplained chronic cough

MedGen UID:
1801507
•Concept ID:
C4552485
•
Sign or Symptom
Synonym: UCC - unexplained chronic cough
SNOMED CT: UCC - unexplained chronic cough (1204369007); Unexplained chronic cough (1204369007)

Professional guidelines

PubMed

Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
Kum E, Patel M, Diab N, Wahab M, Zeraatkar D, Chu DK, O'Byrne PM, Guyatt GH, Satia I
JAMA 2023 Oct 10;330(14):1359-1369. doi: 10.1001/jama.2023.18035. PMID: 37694849Free PMC Article
Chronic cough in adults: recommendations from an Italian intersociety consensus.
De Vincentis A, Baldi F, Calderazzo M, Caliceti U, Guarnieri G, Lombardi F, Lombardo FP, Maggi S, Onder G, Vaghi A, Zanasi A, Antonelli Incalzi R; Associazione Italiana Pneumologi Ospedalieri (AIPO), Associazione Italiana Studio Tosse (AIST), Consiglio Nazionale delle Ricerche (CNR), Istituto Superiore Sanità (ISS), Società Italiana di Allergologia, Asma ed Immunologia Clinica (SIAAIC), Società Italiana di Geriatria e Gerontologia (SIGG), Società Italiana di Medicina Generale e delle Cure Primarie (SIMG), Società Italiana di Pneumologia (SIP)
Aging Clin Exp Res 2022 Jul;34(7):1529-1550. Epub 2022 Jun 6 doi: 10.1007/s40520-022-02154-4. PMID: 35666453
Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report.
Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS; CHEST Expert Cough Panel
Chest 2016 Jan;149(1):27-44. Epub 2016 Jan 6 doi: 10.1378/chest.15-1496. PMID: 26426314Free PMC Article

Recent clinical studies

Etiology

Baseline Cohort Profile of the Korean Chronic Cough Registry: A Multicenter, Prospective, Observational Study.
Jo EJ, Lee JH, Won HK, Kang N, Kang SY, Lee SE, Lee JH, Kim MY, Shim JS, An J, Yoo Y, Park SY, Kim BK, Moon JY, Park HK, Kim MH, Kwon HS, Kim SH, Kim SH, Chang YS, Kim SH, Birring SS, Lee BJ, Song WJ
Lung 2023 Oct;201(5):477-488. Epub 2023 Sep 2 doi: 10.1007/s00408-023-00644-4. PMID: 37658853
Predictors of treatment response to pregabalin in unexplained or refractory chronic cough.
Saint-Pierre MD
Respir Med 2023 Nov;218:107396. Epub 2023 Aug 30 doi: 10.1016/j.rmed.2023.107396. PMID: 37657533
The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
McGarvey L, Sher M, Shvarts YG, Lu S, Wu WC, Xu P, Schelfhout J, La Rosa C, Nguyen AM, Reyfman PA, Afzal AS
Lung 2023 Apr;201(2):111-118. Epub 2023 Mar 6 doi: 10.1007/s00408-023-00606-w. PMID: 36879087Free PMC Article
Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators
Lancet 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5. PMID: 35248186
Validation of a visual analog scale for assessing cough severity in patients with chronic cough.
Martin Nguyen A, Bacci ED, Vernon M, Birring SS, Rosa C, Muccino D, Schelfhout J
Ther Adv Respir Dis 2021 Jan-Dec;15:17534666211049743. doi: 10.1177/17534666211049743. PMID: 34697975Free PMC Article

Diagnosis

Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators
Lancet 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5. PMID: 35248186
Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.
McCrea JB, Hussain A, Ma B, Garrett GC, Evers R, Laabs JE, Stoch SA, Iwamoto M
Clin Pharmacol Drug Dev 2022 Mar;11(3):406-412. Epub 2021 Nov 24 doi: 10.1002/cpdd.1047. PMID: 34821075Free PMC Article
Validation of a visual analog scale for assessing cough severity in patients with chronic cough.
Martin Nguyen A, Bacci ED, Vernon M, Birring SS, Rosa C, Muccino D, Schelfhout J
Ther Adv Respir Dis 2021 Jan-Dec;15:17534666211049743. doi: 10.1177/17534666211049743. PMID: 34697975Free PMC Article
Clinical application of volumetric absorptive microsampling to the gefapixant development program.
Roadcap B, Hussain A, Dreyer D, Carter K, Dube N, Xu Y, Anderson M, Berthier E, Vazvaei F, Bateman K, Woolf E
Bioanalysis 2020 Jul;12(13):893-904. Epub 2020 Jul 10 doi: 10.4155/bio-2020-0074. PMID: 32648772
Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report.
Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS; CHEST Expert Cough Panel
Chest 2016 Jan;149(1):27-44. Epub 2016 Jan 6 doi: 10.1378/chest.15-1496. PMID: 26426314Free PMC Article

Therapy

Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
Kum E, Patel M, Diab N, Wahab M, Zeraatkar D, Chu DK, O'Byrne PM, Guyatt GH, Satia I
JAMA 2023 Oct 10;330(14):1359-1369. doi: 10.1001/jama.2023.18035. PMID: 37694849Free PMC Article
Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators
Lancet 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5. PMID: 35248186
Validation of a visual analog scale for assessing cough severity in patients with chronic cough.
Martin Nguyen A, Bacci ED, Vernon M, Birring SS, Rosa C, Muccino D, Schelfhout J
Ther Adv Respir Dis 2021 Jan-Dec;15:17534666211049743. doi: 10.1177/17534666211049743. PMID: 34697975Free PMC Article
Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough.
Mazzone SB, McGarvey L
Clin Pharmacol Ther 2021 Mar;109(3):619-636. Epub 2020 Aug 28 doi: 10.1002/cpt.2003. PMID: 32748976Free PMC Article
Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report.
Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS; CHEST Expert Cough Panel
Chest 2016 Jan;149(1):27-44. Epub 2016 Jan 6 doi: 10.1378/chest.15-1496. PMID: 26426314Free PMC Article

Prognosis

Predictors of treatment response to pregabalin in unexplained or refractory chronic cough.
Saint-Pierre MD
Respir Med 2023 Nov;218:107396. Epub 2023 Aug 30 doi: 10.1016/j.rmed.2023.107396. PMID: 37657533
Clinical application of volumetric absorptive microsampling to the gefapixant development program.
Roadcap B, Hussain A, Dreyer D, Carter K, Dube N, Xu Y, Anderson M, Berthier E, Vazvaei F, Bateman K, Woolf E
Bioanalysis 2020 Jul;12(13):893-904. Epub 2020 Jul 10 doi: 10.4155/bio-2020-0074. PMID: 32648772
Tachyphylaxis and Dependence in Pharmacotherapy for Unexplained Chronic Cough.
Bowen AJ, Huang TL, Nowacki AS, Trask D, Kaltenbach J, Taliercio R, Benninger MS, Milstein CF, Bryson PC
Otolaryngol Head Neck Surg 2018 Oct;159(4):705-711. Epub 2018 Jul 17 doi: 10.1177/0194599818788062. PMID: 30016197
Short- and Long-term Effects of Neuromodulators for Unexplained Chronic Cough.
Bowen AJ, Nowacki AS, Contrera K, Trask D, Kaltenbach J, Milstein CF, Adessa M, Benninger MS, Taliercio R, Bryson PC
Otolaryngol Head Neck Surg 2018 Sep;159(3):508-515. Epub 2018 Apr 10 doi: 10.1177/0194599818768517. PMID: 29634404
Gastroesophageal reflux disease and chronic cough.
Tokayer AZ
Lung 2008;186 Suppl 1:S29-34. Epub 2008 Jan 24 doi: 10.1007/s00408-007-9057-3. PMID: 18214605

Clinical prediction guides

Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
Kum E, Patel M, Diab N, Wahab M, Zeraatkar D, Chu DK, O'Byrne PM, Guyatt GH, Satia I
JAMA 2023 Oct 10;330(14):1359-1369. doi: 10.1001/jama.2023.18035. PMID: 37694849Free PMC Article
Predictors of treatment response to pregabalin in unexplained or refractory chronic cough.
Saint-Pierre MD
Respir Med 2023 Nov;218:107396. Epub 2023 Aug 30 doi: 10.1016/j.rmed.2023.107396. PMID: 37657533
The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
McGarvey L, Sher M, Shvarts YG, Lu S, Wu WC, Xu P, Schelfhout J, La Rosa C, Nguyen AM, Reyfman PA, Afzal AS
Lung 2023 Apr;201(2):111-118. Epub 2023 Mar 6 doi: 10.1007/s00408-023-00606-w. PMID: 36879087Free PMC Article
Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators
Lancet 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5. PMID: 35248186
Validation of a visual analog scale for assessing cough severity in patients with chronic cough.
Martin Nguyen A, Bacci ED, Vernon M, Birring SS, Rosa C, Muccino D, Schelfhout J
Ther Adv Respir Dis 2021 Jan-Dec;15:17534666211049743. doi: 10.1177/17534666211049743. PMID: 34697975Free PMC Article

Recent systematic reviews

Understanding the economic burden of chronic cough: a systematic literature review.
Bali V, Adriano A, Byrne A, Akers KG, Frederickson A, Schelfhout J
BMC Pulm Med 2023 Oct 31;23(1):416. doi: 10.1186/s12890-023-02709-9. PMID: 37907889Free PMC Article
Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
Kum E, Patel M, Diab N, Wahab M, Zeraatkar D, Chu DK, O'Byrne PM, Guyatt GH, Satia I
JAMA 2023 Oct 10;330(14):1359-1369. doi: 10.1001/jama.2023.18035. PMID: 37694849Free PMC Article
Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials.
Ramadan A, El-Samahy M, Elrosasy A, Al-Tawil M, Abdelaziz A, Soliman MA, Abouzid M
Pulm Pharmacol Ther 2023 Dec;83:102252. Epub 2023 Sep 9 doi: 10.1016/j.pupt.2023.102252. PMID: 37678663
Speech and language therapy for management of chronic cough.
Slinger C, Mehdi SB, Milan SJ, Dodd S, Matthews J, Vyas A, Marsden PA
Cochrane Database Syst Rev 2019 Jul 23;7(7):CD013067. doi: 10.1002/14651858.CD013067.pub2. PMID: 31335963Free PMC Article
Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report.
Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS; CHEST Expert Cough Panel
Chest 2016 Jan;149(1):27-44. Epub 2016 Jan 6 doi: 10.1378/chest.15-1496. PMID: 26426314Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...